DE3805150A1 - Gentechnologisches verfahren zur herstellung von polypeptiden - Google Patents
Gentechnologisches verfahren zur herstellung von polypeptidenInfo
- Publication number
- DE3805150A1 DE3805150A1 DE3805150A DE3805150A DE3805150A1 DE 3805150 A1 DE3805150 A1 DE 3805150A1 DE 3805150 A DE3805150 A DE 3805150A DE 3805150 A DE3805150 A DE 3805150A DE 3805150 A1 DE3805150 A1 DE 3805150A1
- Authority
- DE
- Germany
- Prior art keywords
- galactosidase
- gene
- fragment
- polypeptide
- codons
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 51
- 229920001184 polypeptide Polymers 0.000 title claims description 50
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 50
- 108090000623 proteins and genes Proteins 0.000 title claims description 50
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 80
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 76
- 239000012634 fragment Substances 0.000 claims description 70
- 108020004705 Codon Proteins 0.000 claims description 51
- 150000001413 amino acids Chemical class 0.000 claims description 29
- 235000001014 amino acid Nutrition 0.000 claims description 28
- 238000003776 cleavage reaction Methods 0.000 claims description 25
- 230000007017 scission Effects 0.000 claims description 25
- 108010076181 Proinsulin Proteins 0.000 claims description 20
- 102000037865 fusion proteins Human genes 0.000 claims description 19
- 108020001507 fusion proteins Proteins 0.000 claims description 19
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 17
- 229930182817 methionine Natural products 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 12
- 235000018417 cysteine Nutrition 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 12
- 230000001105 regulatory effect Effects 0.000 claims description 10
- 239000004475 Arginine Substances 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 9
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 230000002255 enzymatic effect Effects 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 5
- 230000004927 fusion Effects 0.000 claims description 5
- 102000055006 Calcitonin Human genes 0.000 claims description 4
- 108060001064 Calcitonin Proteins 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 229960004015 calcitonin Drugs 0.000 claims description 4
- 102000007625 Hirudins Human genes 0.000 claims description 3
- 108010007267 Hirudins Proteins 0.000 claims description 3
- 108010002350 Interleukin-2 Proteins 0.000 claims description 3
- 102000000588 Interleukin-2 Human genes 0.000 claims description 3
- 108010086019 Secretin Proteins 0.000 claims description 3
- 102100037505 Secretin Human genes 0.000 claims description 3
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 3
- 229940006607 hirudin Drugs 0.000 claims description 3
- 229960002101 secretin Drugs 0.000 claims description 3
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 claims description 3
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims description 2
- 102100022831 Somatoliberin Human genes 0.000 claims description 2
- 101710142969 Somatoliberin Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 description 47
- 108020004414 DNA Proteins 0.000 description 32
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 28
- 229940024606 amino acid Drugs 0.000 description 22
- 108091008146 restriction endonucleases Proteins 0.000 description 15
- 238000010276 construction Methods 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 231100000350 mutagenesis Toxicity 0.000 description 8
- 238000002703 mutagenesis Methods 0.000 description 8
- 229920002401 polyacrylamide Polymers 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000004904 shortening Methods 0.000 description 7
- 102000004142 Trypsin Human genes 0.000 description 6
- 108090000631 Trypsin Proteins 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 239000012588 trypsin Substances 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000001502 gel electrophoresis Methods 0.000 description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000002464 Galactosidases Human genes 0.000 description 3
- 108010093031 Galactosidases Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000004678 hydrides Chemical group 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 231100000219 mutagenic Toxicity 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 229940044627 gamma-interferon Drugs 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 108010066381 preproinsulin Proteins 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 102000003670 Carboxypeptidase B Human genes 0.000 description 1
- 108090000087 Carboxypeptidase B Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- NCSHGROOCJHAFK-UHFFFAOYSA-N [Cl].N#CC#N Chemical compound [Cl].N#CC#N NCSHGROOCJHAFK-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108010068072 salmon calcitonin Proteins 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/585—Calcitonins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
- C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Diabetes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Priority Applications (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3805150A DE3805150A1 (de) | 1987-04-11 | 1988-02-19 | Gentechnologisches verfahren zur herstellung von polypeptiden |
| DE8888105438T DE3877035D1 (de) | 1987-04-11 | 1988-04-06 | Gentechnologisches verfahren zur herstellung von polypeptiden. |
| AT88105438T ATE84076T1 (de) | 1987-04-11 | 1988-04-06 | Gentechnologisches verfahren zur herstellung von polypeptiden. |
| EP88105438A EP0286956B1 (de) | 1987-04-11 | 1988-04-06 | Gentechnologisches Verfahren zur Herstellung von Polypeptiden |
| FI881617A FI881617A7 (fi) | 1987-04-11 | 1988-04-07 | Genteknologiskt foerfarande foer framstaellning av polypeptider. |
| NO881548A NO881548L (no) | 1987-04-11 | 1988-04-08 | Genteknologisk fremgangsmaate for fremstilling av polypeptider. |
| NZ224184A NZ224184A (en) | 1987-04-11 | 1988-04-08 | Modification of beta-galactosidase regulatory gene; use in genetic engineering |
| IL86023A IL86023A (en) | 1987-04-11 | 1988-04-10 | Genetic engineering process for the preparation of polypeptides containing -galactosidase or a' -galactosidase fragment' |
| JP63088888A JPS63263087A (ja) | 1987-04-11 | 1988-04-11 | ポリペプチドの遺伝子工学的製造法 |
| KR1019880004072A KR880012758A (ko) | 1987-04-11 | 1988-04-11 | 폴리펩타이드의 유전공학적 제조방법 |
| DK196188A DK196188A (da) | 1987-04-11 | 1988-04-11 | Fremgangsmaade til fremstilling af et polypeptid, der kan kodes for genetisk, og anvendelse heraf |
| AU14469/88A AU603883B2 (en) | 1987-04-11 | 1988-04-11 | Genetic engineering process for the preparation of polypeptides |
| PT87211A PT87211B (pt) | 1987-04-11 | 1988-04-11 | Processo para a preparacao de polipeptideos por manipulacao genetica |
| GR930400200T GR3007417T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1987-04-11 | 1993-03-19 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3712361 | 1987-04-11 | ||
| DE3805150A DE3805150A1 (de) | 1987-04-11 | 1988-02-19 | Gentechnologisches verfahren zur herstellung von polypeptiden |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3805150A1 true DE3805150A1 (de) | 1988-10-20 |
Family
ID=25854588
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3805150A Withdrawn DE3805150A1 (de) | 1987-04-11 | 1988-02-19 | Gentechnologisches verfahren zur herstellung von polypeptiden |
| DE8888105438T Expired - Fee Related DE3877035D1 (de) | 1987-04-11 | 1988-04-06 | Gentechnologisches verfahren zur herstellung von polypeptiden. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE8888105438T Expired - Fee Related DE3877035D1 (de) | 1987-04-11 | 1988-04-06 | Gentechnologisches verfahren zur herstellung von polypeptiden. |
Country Status (12)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK175535B1 (da) * | 1987-03-04 | 2004-11-29 | Daiichi Suntory Pharma Co Ltd | Fremgangsmåde til fremstilling af et fysiologisk aktivt cysteinholdigt peptid |
| DE3716722A1 (de) * | 1987-05-19 | 1988-12-01 | Hoechst Ag | Gentechnologisches verfahren zur herstellung von angiogeninen |
| DE3844211A1 (de) * | 1988-12-29 | 1990-07-05 | Hoechst Ag | Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
| US5179196A (en) * | 1989-05-04 | 1993-01-12 | Sri International | Purification of proteins employing ctap-iii fusions |
| US5527687A (en) * | 1993-05-25 | 1996-06-18 | American Cyanamid Company | Enzyme induction screen for ergosterol biosynthesis inhibitors |
| CA2198966C (en) * | 1996-03-04 | 2011-06-21 | Yuji Suzuki | Method for cleaving chimeric protein using processing enzyme |
| DE59711533D1 (de) | 1996-07-26 | 2004-05-27 | Aventis Pharma Gmbh | Insulinderivate mit erhöhter Zinkbindung |
| DE19825447A1 (de) | 1998-06-06 | 1999-12-09 | Hoechst Marion Roussel De Gmbh | Neue Insulinanaloga mit erhöhter Zinkbildung |
| WO2014164466A1 (en) * | 2013-03-12 | 2014-10-09 | E. I. Du Pont De Nemours And Company | Methods for the identification of variant recognition sites for rare-cutting engineered double-strand-break-inducing agents and compositions and uses thereof |
| KR20200080747A (ko) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법 |
| KR20200080748A (ko) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL55890A (en) * | 1977-11-08 | 1984-01-31 | Genentech Inc | Method and means for polypeptide production involving expression of a heterologous gene,and as products therefrom recombinant microbial cloning vehicles containing said gene |
| JPS6028994A (ja) * | 1983-07-08 | 1985-02-14 | Wakunaga Seiyaku Kk | 〔２１―ロイシン〕ヒトウロガストロン |
| WO1985000831A1 (en) * | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of insulin-like growth factor |
| DK175535B1 (da) * | 1987-03-04 | 2004-11-29 | Daiichi Suntory Pharma Co Ltd | Fremgangsmåde til fremstilling af et fysiologisk aktivt cysteinholdigt peptid |
| DE3715033A1 (de) * | 1987-05-06 | 1988-11-17 | Hoechst Ag | Verfahren zur isolierung von fusionsproteinen |
-
1988
- 1988-02-19 DE DE3805150A patent/DE3805150A1/de not_active Withdrawn
- 1988-04-06 DE DE8888105438T patent/DE3877035D1/de not_active Expired - Fee Related
- 1988-04-06 EP EP88105438A patent/EP0286956B1/de not_active Expired - Lifetime
- 1988-04-07 FI FI881617A patent/FI881617A7/fi not_active IP Right Cessation
- 1988-04-08 NZ NZ224184A patent/NZ224184A/xx unknown
- 1988-04-08 NO NO881548A patent/NO881548L/no unknown
- 1988-04-10 IL IL86023A patent/IL86023A/xx unknown
- 1988-04-11 AU AU14469/88A patent/AU603883B2/en not_active Ceased
- 1988-04-11 PT PT87211A patent/PT87211B/pt not_active IP Right Cessation
- 1988-04-11 DK DK196188A patent/DK196188A/da not_active Application Discontinuation
- 1988-04-11 JP JP63088888A patent/JPS63263087A/ja active Pending
- 1988-04-11 KR KR1019880004072A patent/KR880012758A/ko not_active Ceased
-
1993
- 1993-03-19 GR GR930400200T patent/GR3007417T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU603883B2 (en) | 1990-11-29 |
| KR880012758A (ko) | 1988-11-29 |
| NZ224184A (en) | 1989-10-27 |
| FI881617A7 (fi) | 1988-10-12 |
| EP0286956B1 (de) | 1992-12-30 |
| IL86023A (en) | 1993-01-31 |
| NO881548L (no) | 1988-10-12 |
| EP0286956A3 (en) | 1989-04-05 |
| GR3007417T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1993-07-30 |
| NO881548D0 (no) | 1988-04-08 |
| JPS63263087A (ja) | 1988-10-31 |
| PT87211B (pt) | 1992-07-31 |
| IL86023A0 (en) | 1988-09-30 |
| DK196188A (da) | 1988-10-12 |
| AU1446988A (en) | 1988-10-13 |
| PT87211A (pt) | 1988-05-01 |
| EP0286956A2 (de) | 1988-10-19 |
| DK196188D0 (da) | 1988-04-11 |
| DE3877035D1 (de) | 1993-02-11 |
| FI881617A0 (fi) | 1988-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3850995T2 (de) | Sekretion eines dem Insulin ähnlichen Wachstumsfaktors in E. coli. | |
| DE3886408T2 (de) | Synthetische hefe-signalpeptide. | |
| DE3486216T2 (de) | Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren. | |
| DE3785864T2 (de) | Verfahren zur Herstellung von menschlichem Epidermalwachstumsfaktor und dessen Analogen. | |
| DE69032743T2 (de) | Herstellung von fusionsproteinen | |
| DE69018920T2 (de) | Verwendung von dns-fragmenten, die ein signalpeptid kodieren zur sekretion von reifen proteinen in rekombinanten hefen, expressions-kassetten, transformierte hefen und verfahren zur herstellung dieser proteine. | |
| EP0211299B1 (de) | Fusionsproteine, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DE69521752T2 (de) | Verfahren für die Herstellung von Proteinen | |
| EP0229998B1 (de) | Fusionsproteine mit eukaryotischem Ballastanteil | |
| DE3587875T2 (de) | Rekombinantverfahren zur herstellung von serinproteaseinhibitoren, sowie dns-sequenzen dazu. | |
| DE3752063T2 (de) | Funktioneller DNS-Block und für Hirudin kodierendes Plasmid, transformierte Hefe aud Verfahren zur Herstellung von Hirudin. | |
| EP0286956B1 (de) | Gentechnologisches Verfahren zur Herstellung von Polypeptiden | |
| DD212403A5 (de) | Verfahren zur synthetisierung von rinderwachstumshormon | |
| DE60209883T2 (de) | Übersekretierte peptide, deren herstellung, und gleichzeitige verbesserung der sekretierten form eines oder mehrerer anderer polypeptide | |
| DE69735242T2 (de) | N-terminal verlängerte proteine exprimiert in hefe | |
| EP0453969B1 (de) | Verfahren zur Herstellung von Fremdproteinen in Streptomyceten | |
| DE3609924A1 (de) | Herstellung des epidermalen wachstumsfaktors | |
| EP0292763A2 (de) | Gentechnologisches Verfahren zur Herstellung von Angiogeninen | |
| DE69634757T2 (de) | Vektor zur expression von n-terminal verlängerten proteinen in hefezellen | |
| DE69630630T2 (de) | Staphylococcus aureus V8 Protease Mutanten | |
| EP0367163B1 (de) | Verfahren zur Herstellung eines Insulin-Vorprodukts in Streptomyceten | |
| DE68922549T2 (de) | Signalpeptid und dafür kodierende DNS-Sequenzen. | |
| EP0289936B1 (de) | Verfahren zur Herstellung von Fremdproteinen in Streptomyceten | |
| EP0393039B1 (en) | Process for producing peptides by specific cleavage of fusion proteins with collagenases obtained by genetic engineering | |
| EP0951539A1 (de) | Vektor-system zur klonierung von dna |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8130 | Withdrawal |